Cochrane · systematic review · CD004900
Botulinum toxin type A therapy for blepharospasm
Duarte, GS, Rodrigues, FB, Marques, RE, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Movement DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
1
Included studies
NR
No studies 1 · 14.3%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 42.9%Moderate 2 · 28.6%High 1 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Botulinum toxin type A compared to placebo for blepharospasm
Population: adults with blepharospasm
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Blepharospasm‐specific severity ( Botulinum toxin type A vs placebo | no estimate extracted | NR | Moderate Downgraded: risk of bias |
Adverse events (reported at any time) (2 RCT, 169 participants) Botulinum toxin type A vs placebo | RR 1.18 [0.87, 1.6] | NR | Low Downgraded: risk of bias, imprecision |
Subjective participant evaluation ( Botulinum toxin type A vs placebo | no estimate extracted | NR | High |
Frequency of blepharospasm‐specific involuntary movements ( Botulinum toxin type A vs placebo | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision |
Health‐related quality of life Botulinum toxin type A vs placebo | no estimate extracted | NR | No studies |
Tolerability (number of dropouts; reported at any time) (2 RCT, 169 participants) Botulinum toxin type A vs placebo | RR 1.44 [0.31, 6.79] | NR | Moderate Downgraded: imprecision |
Duration of effect (when effects started to wane) Botulinum toxin type A vs placebo | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision |